JP2022518523A5 - - Google Patents

Info

Publication number
JP2022518523A5
JP2022518523A5 JP2021543122A JP2021543122A JP2022518523A5 JP 2022518523 A5 JP2022518523 A5 JP 2022518523A5 JP 2021543122 A JP2021543122 A JP 2021543122A JP 2021543122 A JP2021543122 A JP 2021543122A JP 2022518523 A5 JP2022518523 A5 JP 2022518523A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
solvate
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543122A
Other languages
English (en)
Japanese (ja)
Other versions
JP7588077B2 (ja
JP2022518523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014777 external-priority patent/WO2020154492A1/en
Publication of JP2022518523A publication Critical patent/JP2022518523A/ja
Publication of JP2022518523A5 publication Critical patent/JP2022518523A5/ja
Application granted granted Critical
Publication of JP7588077B2 publication Critical patent/JP7588077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543122A 2019-01-24 2020-01-23 Gpr35モジュレーター Active JP7588077B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (3)

Publication Number Publication Date
JP2022518523A JP2022518523A (ja) 2022-03-15
JP2022518523A5 true JP2022518523A5 (https=) 2023-02-07
JP7588077B2 JP7588077B2 (ja) 2024-11-21

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543122A Active JP7588077B2 (ja) 2019-01-24 2020-01-23 Gpr35モジュレーター

Country Status (13)

Country Link
US (2) US11053251B2 (https=)
EP (1) EP3914256B1 (https=)
JP (1) JP7588077B2 (https=)
KR (1) KR102863894B1 (https=)
CN (1) CN113631168B (https=)
AU (1) AU2020210930B2 (https=)
BR (1) BR112021014566A2 (https=)
CA (1) CA3127786A1 (https=)
IL (1) IL285074B2 (https=)
MA (1) MA54825A (https=)
MX (1) MX2021008941A (https=)
TW (1) TWI845600B (https=)
WO (1) WO2020154492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
EP4185379A4 (en) * 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) * 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
WO2005085867A2 (en) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
KR102481020B1 (ko) 2014-06-29 2022-12-26 프로파일 프러덕츠 엘엘씨 나무껍질 및 목재 섬유 성장 배지
WO2018195328A1 (en) * 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3920953A4 (en) 2019-02-08 2022-12-14 Cedars-Sinai Medical Center METHODS, SYSTEMS AND KITS FOR THE TREATMENT OF INFLAMMATORY DISEASES TARGETED FOR IL18R1
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
EP4185379A4 (en) 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
AU2021377688A1 (en) 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Similar Documents

Publication Publication Date Title
JP2022518523A5 (https=)
JP2017512833A5 (https=)
JP2021534124A5 (https=)
JP2022553841A5 (https=)
JP2024520481A5 (https=)
JP2021527638A5 (https=)
JP2022529311A5 (https=)
JP2015536947A5 (https=)
JP2016506960A5 (https=)
JP2016505512A5 (https=)
JP2015505296A5 (https=)
JP2024543512A5 (https=)
JP2020527588A5 (https=)
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
JP2023553835A5 (https=)
JP2021523200A5 (https=)
JP2020527175A5 (https=)
JP2013510885A5 (https=)
JP2021514001A5 (https=)
JP2016503403A5 (https=)
JP2018514544A5 (https=)
JP2021526123A5 (https=)
JP2012092103A5 (https=)
JP2022519696A5 (https=)
JP2023520925A5 (https=)